Evidence map›Paper›PMID 30390209›Full record

ArticleEndocrine2019

Limited short-term effects on human prostate cancer xenograft growth and epidermal growth factor receptor gene expression by the ghrelin receptor antagonist [D-Lys

Michelle L Maugham, Inge Seim, Patrick B Thomas, Gabrielle J Crisp, Esha T Shah, Adrian C Herington, Laura S Gregory, Colleen C Nelson, Penny L Jeffery, Lisa K Chopin

Abstract read
PubMed Publisher
In one paragraph

Article in Endocrine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Michelle L MaughamGhrelin Research Group, Institute of Health and Biomedical Innovation, Translational Research Institute and School of Biomedical Sciences, Queensland University of Technology, Brisbane, QLD, Australia.
Inge SeimGhrelin Research Group, Institute of Health and Biomedical Innovation, Translational Research Institute and School of Biomedical Sciences, Queensland University of Technology, Brisbane, QLD, Australia.
Patrick B ThomasGhrelin Research Group, Institute of Health and Biomedical Innovation, Translational Research Institute and School of Biomedical Sciences, Queensland University of Technology, Brisbane, QLD, Australia.
Gabrielle J CrispGhrelin Research Group, Institute of Health and Biomedical Innovation, Translational Research Institute and School of Biomedical Sciences, Queensland University of Technology, Brisbane, QLD, Australia.
Esha T ShahGhrelin Research Group, Institute of Health and Biomedical Innovation, Translational Research Institute and School of Biomedical Sciences, Queensland University of Technology, Brisbane, QLD, Australia.
Adrian C HeringtonGhrelin Research Group, Institute of Health and Biomedical Innovation, Translational Research Institute and School of Biomedical Sciences, Queensland University of Technology, Brisbane, QLD, Australia.
Laura S GregorySkeletal Biology and Forensic Anthropology Research Laboratory, Cancer Program, School of Biomedical Sciences, Institute of Health and Biomedical Innovation, Translational Research Institute, Queensland University of Technology, Brisbane, QLD, Australia.
Colleen C NelsonAustralian Prostate Cancer Research Centre - Queensland, Princess Alexandra Hospital, Institute of Health and Biomedical Innovation, Translational Research Institute, Queensland University of Technology, Brisbane, QLD, Australia.
Penny L JefferyGhrelin Research Group, Institute of Health and Biomedical Innovation, Translational Research Institute and School of Biomedical Sciences, Queensland University of Technology, Brisbane, QLD, Australia.
Lisa K ChopinGhrelin Research Group, Institute of Health and Biomedical Innovation, Translational Research Institute and School of Biomedical Sciences, Queensland University of Technology, Brisbane, QLD, Australia. l.chopin@qut.edu.au.
Translational Research Institute · AUQueensland University of Technology · AUPrincess Alexandra Hospital · AU

Funding

Australian Research Council (AU) DP140100249Cancer Council Queensland 1098565National Health and Medical Research Council Australia 1059021
6 · The paper itself

Abstract

purposeThe ghrelin axis regulates many physiological functions (including appetite, metabolism, and energy balance) and plays a role in disease processes. As ghrelin stimulates prostate cancer proliferation, the ghrelin receptor antagonist [D-Lys

methodsNOD/SCID mice with PC3 prostate cancer xenografts were administered 20 nmoles/mouse [D-Lys

resultsWe demonstrate here that daily intraperitoneal injection of 20 nmoles/mouse [D-Lys

conclusionsWe show that [D-Lys

Indexed as

AnimalsCell ProliferationErbB ReceptorsGene ExpressionHeterograftsHumansMaleMiceMice, Inbred NODMice, SCIDOligopeptidesPC-3 CellsProstatic NeoplasmsReceptors, GhrelinErbB Receptorsgrowth hormone releasing hexapeptideOligopeptidesReceptors, Ghrelin[D-Lys3]-GHRP-6GhrelinGhrelin receptor antagonistPC3Prostate cancerXenograft

Identifiers

PMID30390209
OpenAlexW2898950613

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.